Summary & Overview
CPT 90668: Influenza Vaccine, Split Virus for Pandemic Strain
CPT code 90668 identifies a split-virus influenza vaccine formulated and administered intramuscularly to protect against a pandemic influenza strain. This immunization code matters nationally because pandemic influenza vaccines are central to public health response, mass immunization campaigns, and payer coverage policies during widespread outbreaks. Accurate coding ensures vaccine tracking, billing consistency, and alignment with public health reporting needs.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical clinical setting for administration, and the policy and billing contexts that influence use of the code. The publication includes benchmarks and payer coverage patterns where available, summaries of relevant policy updates affecting pandemic influenza immunization coding and billing, and clinical context for vaccine formulation and delivery.
The content is intended for national audiences including health system billing leads, compliance officers, and policy analysts who need clear, actionable descriptions of the code’s purpose and common administrative considerations. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 90668 represents an influenza vaccine, split virus formulation, administered intramuscularly to protect against a pandemic influenza strain. The service type is vaccine administration for pandemic influenza prevention. The typical site of service is outpatient settings such as clinics, physician offices, and pharmacies where intramuscular vaccinations are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a primary care clinic, occupational health clinic, community health center, or mass vaccination site during a pandemic influenza outbreak seeking immunization. The patient is screened for contraindications (severe allergic reaction to prior influenza vaccine or vaccine components, acute moderate or severe illness) and provided vaccine information. After informed consent, the clinician (e.g., family medicine physician, nurse practitioner, physician assistant, or registered nurse) administers the intramuscular, split-virus pandemic influenza vaccine using standard intramuscular technique, observes the patient for 15 minutes for immediate adverse reactions (30 minutes for patients with a history of severe allergic reactions), documents lot number, manufacturer, administration site, and vaccine route in the medical record and immunization registry, and issues after-care instructions. Billing is submitted using 90668 for the vaccine product; administration services may be billed separately depending on payer policies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply; standard billing for vaccine product. |
52 |